<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04407481</url>
  </required_header>
  <id_info>
    <org_study_id>20-0277</org_study_id>
    <nct_id>NCT04407481</nct_id>
  </id_info>
  <brief_title>PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)</brief_title>
  <acronym>PENGUIN</acronym>
  <official_title>PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of
      end-stage kidney disease (ESKD). The disorder is characterized by development and continued
      growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60
      years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR)
      and mitochondrial dysfunction which may be causally related to cyst expansion, kidney
      function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a
      potential metabolic mismatch between increased renal energy expenditure and impaired
      substrate utilization, is proposed as a novel unifying early pathway in the development and
      expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption
      and energy utilization in young adults with and without ADPKD, the investigators hope to
      identify novel therapeutic targets to impede development of cyst expansion in future trials.

      The investigators propose to address the specific aims in a cross-sectional study with 20
      adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from
      healthy adults from an ongoing study with similar study design and methods (CROCODILE Study:
      Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For
      this protocol, participants will complete a one day study visit at Children's Hospital
      Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body
      composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal
      O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic
      clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and
      Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the
      hyperinsulinemic-euglycemic clamp.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Renal oxygen consumption</measure>
    <time_frame>30 minutes</time_frame>
    <description>11-C Acetate PET/CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>4.5 hours</time_frame>
    <description>Hyperinsulinemic-Euglycemic Clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for mitochondrial DNA copy number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>3 hours</time_frame>
    <description>Iohexol Clearance Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Renal Plasma Flow (ERPF)</measure>
    <time_frame>2.5 hours</time_frame>
    <description>PAH Clearance Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin-Aldosterone-System Activity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Plasma Renin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin-Aldosterone-System Activity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Angiotensin II levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin-Aldosterone-System Activity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Copeptin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Chitinase-3-like protein 1 (YKL-40) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Kidney Injury Molecule 1 (KIM-1) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Interleukin-18 (IL-18) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for monocyte chemoattractant protein-1 (MCP-1) levels</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Polycystic Kidney Disease, Adult</condition>
  <condition>Polycystic Kidney, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>Adults with autosomal dominant polycystic kidney disease</arm_group_label>
    <description>All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminohippurate Sodium Inj 20%</intervention_name>
    <description>Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)</description>
    <arm_group_label>Adults with autosomal dominant polycystic kidney disease</arm_group_label>
    <other_name>•- Sodium 4-amino hippurate (PAH) inj 20% 2g/10 milliliter (mL) • Para-aminohippurate • Aminohippuric acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol Inj 300 milligrams per milliliter (MG/ML)</intervention_name>
    <description>Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
    <arm_group_label>Adults with autosomal dominant polycystic kidney disease</arm_group_label>
    <other_name>omnipaque 300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET/CT Scan</intervention_name>
    <description>Imaging used to visualize the kidneys and quantify renal metabolic activity</description>
    <arm_group_label>Adults with autosomal dominant polycystic kidney disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During the study, we will collect blood and urine samples for assessment of kidney function
      and kidney injury markers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators propose to address the specific aims in a cross-sectional study with 20
        adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from
        healthy adults from an ongoing study with similar study design and methods.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Autosomal dominant polycystic kidney disease

          -  Age 18-40 years

          -  BMI &gt;= 18.5 and &lt;30 kg/m2

          -  Weight &lt;350 lbs

        Exclusion Criteria:

          -  Diabetes mellitus, based on previous diagnosis

          -  Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) &lt;75ml/min/1.73m2

          -  Pregnancy or nursing

          -  Anemia

          -  Allergy to shellfish or iodine

          -  Vaptan therapy (e.g. tolvaptan)

          -  Uncontrolled hypertension (average ≥140/90 mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allison M Hilkin, BA</last_name>
    <phone>720-777-6148</phone>
    <email>allison.hilkin@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petter M Bjornstad, MD</last_name>
    <phone>720-777-4659</phone>
    <email>petter.bjornstad@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Allison M Hilkin, BA</last_name>
      <phone>720-777-6148</phone>
      <email>allison.hilkin@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Carissa Vinovskis, MS</last_name>
      <phone>720-777-2660</phone>
      <email>carissa.vinovskis@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Petter M Bjornstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

